Company Overview and News
Good morning, my name is Felicia and I will be your conference operator today. At this time I would like to welcome everyone to the MGIC Investment Corporation First Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks there will be a question-and-answer session. [Operator Instructions]. Thank you. Mr. Mike Zimmerman, Senior Vice President of Investor Relations, you may begin your conference.
April 18, 2018: Here are four stocks trading with heavy volume among 15 equities making new 52-week lows in Wednesday’s session. On the NYSE advancers led decliners by about 8 to 7 and on the Nasdaq, advancers led decliners by about the same ratio.
* QTRLY NEW INSURANCE WRITTEN OF $10.6 BILLION COMPARED TO $9.3 BILLION IN Q1 OF 2017.
Document UNITED STATES
April 10, 2018: Here are four stocks trading with heavy volume among 62 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers led decliners by more than 3 to 1 and on the Nasdaq, advancers led decliners by nearly 4 to 1.
Stocks closed up on Monday, but far lower than the midday highs. Stocks were then indicated up large on Tuesday morning in an effort to recapture those gains. The bull market is now over nine years old, and the trend of buying pullbacks has become much more vulnerable to sellers and volatility trades. The climate has become more difficult for investors trying to decide how they want their assets positioned for the rest of 2018 and beyond.
Shares of Leucadia National Corp. jumped 4.4% in premarket after the diversified holding company announced asset sales, a name-change proposal and increased its stock repurchase program. Among the asset sales, the company announced a deal to sell 48% of National Beef to Marfrig Global Foods S.A. for $900 million in cash, which reduces its ownership stake to 31%. The estimated pre-tax gain of the deal is $800 million to $850 million.
China Life Insurance Co. Ltd’s (LFC - Free Report) ) net profit attributable to equity holders was $5.1 billion (RMB 32.2 billion) at the end of 2017, reflecting 68.6% year-over-year growth. The upside was primarily driven by higher revenues.
Pricing power in insurance and reinsurance remains underwhelming, and Arch has been reporting higher expenses and fading reserve releases.
PRA Group Inc.’s (PRAA - Free Report) fourth-quarter 2017 earnings per share of 36 cents missed the Zacks Consensus Estimate of 37 cents by 2.7%. The bottom line, however, rose 9% from 33 cents in the year-ago quarter on higher revenues.
Alleghany Corporation (Y - Free Report) reported fourth-quarter 2017 operating earnings of $9.89 per share, which surpassed the Zacks Consensus Estimate of $7.58 by 30.5%. Moreover, the bottom line surged 40.9% from the year-ago quarter.
ProAssurance Corporation’s (PRA - Free Report) fourth-quarter 2017 operating earnings per share of 55 cents missed the Zacks Consensus Estimate by 11%. Also, the bottom line declined 33.7% year over year due to lower revenues.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET